Becker's Healthcare March 25, 2024
Madeline Ashley

Medicare total spending hit $5.7 billion in 2022 for GLP-1 drugs such as Ozempic, Wegovy and Mounjaro, up from $57 million in 2018, according to a March 22 KFF analysis.

GLP-1 drugs were originally developed to treat Type 2 diabetes but have since gained popularity as medications used to tackle obesity.

While Medicare is not allowed under existing law to cover the drugs for weight loss, Medicare Part D plans can cover them for other medically accepted indications, such as reducing cardiovascular risk, according to a recent...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, CMS, Govt Agencies, Insurance, Medicare, Patient / Consumer, Pharma / Biotech, Provider, Survey / Study, Trends
Related Articles:
Innovation — but at what price? CMMI Under the Microscope
What’s Behind Slow Uptake of Rural Emergency Hospital Designation?
Improving Access To Medigap When Beneficiaries Leave Medicare Advantage
CMS Advises Preparatory Steps for Anticipated PrEP Coverage Transition to Medicare Part B
GOP jumps on chance to bash Biden on Medicare

Share This Article